ESR1 S463P

CI-VAR-00004072Explore in graph →NP_000116.2:p.Ser463ProNM_000125.3:c.1387T>CClinVar 375934 CIViC 692 rs1057519714

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ESR1 S463P	Palbociclib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4815 In a phase 3 clinical trial (NCT01942135) of 360 premenopausal and postmenopausal women with advanced, hormone receptor-positive breast cancer who had progressed during prior endocrine therapy, patien… (full text at CIViC) PMID 27269946 · Fribbens et al., 2016 · Open in CIViC	civic
Estrogen Receptor-positive Breast Cancer2unmapped disease
ESR1 S463P	Aromatase Inhibitor	Predictive	D	Supports Resistance	2	accepted	EID1727 ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. …

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.